Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2019-09-19
DOI
10.2217/fon-2019-0298
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT).
- (2019) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
- (2019) David Michael Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
- (2019) Joaquin Mateo et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer
- (2019) Shona Lang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
- (2018) Veda N. Giri et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
- (2017) Matti Annala et al. EUROPEAN UROLOGY
- Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA.
- (2017) Werner J. Struss et al. JOURNAL OF CLINICAL ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer
- (2017) Ming Cui et al. Oncotarget
- Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer
- (2017) Likun Li et al. Science Signaling
- Mutations in BRCA2 and taxane resistance in prostate cancer
- (2017) Cathleen Nientiedt et al. Scientific Reports
- Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma
- (2016) Sung Hee Lim et al. Asia-Pacific Journal of Clinical Oncology
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Implications of High Rates of Metastatic Prostate Cancer inBRCA2Mutation Carriers
- (2016) Stephanie Gleicher et al. PROSTATE
- Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment
- (2016) A Sanchez et al. PROSTATE CANCER AND PROSTATIC DISEASES
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
- (2015) Elena Castro et al. EUROPEAN UROLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in malignant pleural effusion in patients with lung cancer
- (2014) Chun-hua Xu et al. Asia-Pacific Journal of Clinical Oncology
- Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
- (2013) S. K. Sandhu et al. ANNALS OF ONCOLOGY
- Investigation of Genetic Polymorphisms Related to the Outcome of Radiotherapy for Prostate Cancer Patients
- (2013) Hellen Silva Cintra et al. DISEASE MARKERS
- GermlineBRCAMutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
- (2013) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
- Association of a XRCC3 polymorphism and rectum mean dose with the risk of acute radio-induced gastrointestinal toxicity in prostate cancer patients
- (2012) Laura Fachal et al. RADIOTHERAPY AND ONCOLOGY
- PD-0531 SNPS IN DNA REPAIR AND DAMAGE DETECTION GENES AND ACUTE NORMAL TISSUE TOXICITY IN PROSTATE CANCER PATIENTS
- (2012) L. Fachal et al. RADIOTHERAPY AND ONCOLOGY
- Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer
- (2011) David J. Gallagher et al. BJU INTERNATIONAL
- The Impact of Genetic Variants in the Double-Stranded DNA Break Repair Pathway on Cancer Control in Men Treated with Radiation for Prostate Cancer
- (2011) P.L. Nguyen et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
- (2010) D. J. Gallagher et al. CLINICAL CANCER RESEARCH
- Sequence Variant Discovery in DNA Repair Genes from Radiosensitive and Radiotolerant Prostate Brachytherapy Patients
- (2009) T. J. Pugh et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now